CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
Total Intravenous Anesthesia (TIVA) Group +2 moredrug
Likely dose
Total Intravenous Anesthesia (TIVA) Group 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07271472
NCT07271472N/ACompleted

Total Intravenous Anesthesia (TIVA), Combined Intravenous-Volatile Anesthesia (CIVA), and Balanced Anesthesia (BAL) on Perioperative Oxidative Stress in Video-Assisted Thoracoscopic Surgery (VATS)

Ataturk University·interventional·Posted Dec 9, 2025·Updated May 14, 2026

In Brief

A clinical study evaluating Total Intravenous Anesthesia (TIVA) Group, Balanced Anesthesia (BAL) Group, and 1 other intervention for VATS and Video Assisted Thoracoscopic Surgery. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The primary objective of our study is to compare the effects of total intravenous anesthesia (TIVA), combined intravenous-volatile anesthesia (CIVA), and balanced anesthesia (BAL) methods on perioperative oxidative stress parameters, such as Malondialdehyde (MDA), Total Oxidant Status (TOS), Total Antioxidant Status (TAS), and Superoxide Dismutase (SOD), in patients undergoing video-assisted thoracoscopic surgery (VATS). The secondary objective is to record perioperative vital parameters, arterial blood gas values obtained at specific stages of the surgery, and the incidence of postoperative nausea and vomiting (PONV).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
2026
First PostedDec 9, 2025
Enrollment StartDec 1, 2025
Primary CompletionMay 1, 2026
Study CompletionMay 2, 2026
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7 months ago

Interventions

Total Intravenous Anesthesia (TIVA) Groupdrug

Anesthesia induction will include 2 mg midazolam, 2-2.5 mg/kg propofol, 0.6-0.9 mg/kg rocuronium, and 1 μg/kg remifentanil. Maintenance will be provided with target-controlled infusion (TCI) propofol at a Ce of 4-6 μg/mL and TCI remifentanil at a Ce of 1.5-3 ng/mL while maintaining the bispectral index (BIS) between 40-60.

Balanced Anesthesia (BAL) Groupdrug

Induction will follow the same protocol as the TIVA group. During maintenance, desflurane 5-7% (MAC 1-1.3) and TCI remifentanil at a Ce of 1.5-3 ng/mL will be administered, targeting a BIS value between 40-60.

Combined Intravenous Volatile Anesthesiadrug

Induction will follow the same protocol as other groups. Maintenance will include TCI propofol at a Ce of 2-4 μg/mL and TCI remifentanil at a Ce of 1.5-3 ng/mL along with 3% desflurane (MAC 0.5), keeping BIS values between 40-60.